Millions of people are expected to test for Alzheimer's in the coming years, yet few support services are available to help people deal with the implications of at-home genetic testing.
The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Two big factors behind the slow debut, experts say, are scant insurance coverage and a long setup time needed by many health systems. Patients who surmount those challenges will step to the head…
Leqembi, the first drug shown to slow Alzheimer’s, has been approved by the FDA, but most U.S. patients will not be able to receive treatment for months.